The market of HIV-1 therapies for multidrug-resistant and pre-exposure prophylaxis (PrEP) is expected to expand due to the expected launch of emerging drugs. The PrEP market is also growing as the reimbursement of PrEP therapies is approved in most countries of 7MM, which ultimately leads to affordability and an increase in the numbers of people from the risk-groups patients taking PrEP treatments.
LAS VEGAS, Nov. 10, 2021 /PRNewswire/ -- DelveInsight's Human Immunodeficiency Virus 1 (HIV-1) Market Insights report proffers a detailed comprehension of HIV-1 market size by treatment, epidemiology, HIV-1 emerging therapies, HIV-1 market drivers, market barriers, ongoing clinical trials, current and forecasted HIV-1 market size fro m 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
As per an analysis by DelveInsight, the market size of Human Immunodeficiency Virus 1 in 7MM was USD 22,663 million in 2020, which is further expected to increase by 2030 at a CAGR of 4.60% for the study period.
DelveInsight estimates that among 7MM, the United States has the highest diagnosed prevalent cases of Human Immunodeficiency Virus with 991,073 cases in 2020.
Key pharmaceutical companies in the Human Immunodeficiency Virus 1 market such as Gilead Sciences, United Biopharma, Frontier Biotechnologies Inc, ViiV Healthcare, GlaxoSmithKline, Janssen, Merck & Co, CytoDyn's, Thera Technologies, and others are involved in the development of HIV Type 1 treatment therapies.
The Human Immunodeficiency Virus 1 pipeline therapies include MK8591B (islatravir + MK-8507), Lenacapavir (GS-6207), UB-421, GSK3640254 (GSK'254), MK-8591A (Islatravir/doravirine), Vyrologix/Leronlimab (PRO 140), Vocabria (cabotegravir), Trogarzo, and many others are expected to launch in the study period 2018-30.
DelveInsight estimates the cost of treating all the people living with HIV is approximately USD 20 billion dollars annually.
HIV stands for Human Immunodeficiency Virus, and if it remains untreated, it can eventually lead to HIV AIDS (acquired immunodeficiency syndrome). HIV is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment. There are two main types of Human Immunodeficiency Virus; HIV-1 and HIV-2.
HIV-1 symptoms include fever, sore throat, fatigue as well as several other flu-like symptoms. HIV-1 infections are marked by a progressive depletion of peripheral CD4+ T cells, T-cell dysfunction, defects in both number and function of (APCs) such as DCs and monocytes, thymic dysfunction, lymphoid destruction, and pan-cellular defects attributed to stem cell dysfunction.
Also, the diagnosed prevalent cases of Human Immunodeficiency Virus in the 7MM were found to be 1,597,714 in 2020 which is expected to increase at a CAGR of 1.75% for the study period of 2018-2030. The diagnosed prevalent cases of HIV were further divided into two broad categories, HIV-1 and HIV-2. There were a total of 990,974 cases of HIV-1 and 99 cases of HIV-2 in 2020 in the United States.
According to DelveInsight, HIV-1 7MM is expected to change in the study period 2018–2030.
There are many medicines available for Human Immunodeficiency Virus regimens. Approved antiretroviral (ARV) HIV drugs are divided into seven drug classes based on how each drug interferes with the Human Immunodeficiency Virus life cycle: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists, post-attachment inhibitors, and integrase strand transfer inhibitors (INSTIs). Fusion inhibitors, CCR5 antagonists, and post-attachment inhibitors can also be known as entry inhibitors as they prevent the entry of HIV into the CD4 cells.
Currently, the marketed product available for Human Immunodeficiency Virus 1 (HIV-1) treatment includes drugs like Pifeltro, Isentress, Truvada, Cabenuva, Genvoya, Dovato, Prezista, Descovy, and several others.
The choice of a Human Immunodeficiency Virus regimen depends on a person's individual needs. When choosing a Human Immunodeficiency Virus regimen, HIV patients and their health care providers take care of many aspects such as possible side effects of HIV medications and potential drug interactions. So, a newer class of potential Human Immunodeficiency Virus treatment therapies are under clinical trials and are expected to launch in the forecast period include Lenacapavir (GS-6207) developed by Gilead Sciences is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development to treat and prevent HIV-1 infection. Lenacapavir's multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for developing long-acting therapy options for people living with or at risk for HIV-1. Another therapy is a next-generation HIV-1 Maturation Inhibitor (MI) that acts during the last step of the Human Immunodeficiency Virus life cycle is GSK3640254 by GlaxoSmithKline/ViiV Healthcare. It binds to HIV-1 Gag, inhibiting the final protease-mediated cleavage event between capsid (CA) protein p24 and spacer peptide 1 (SP1) within the Gag polyprotein. Prevention of Gag polyprotein separation to its component proteins p24/CA and SP1 results in the release of immature, noninfectious virions. Currently, this drug is under investigation in a Phase II clinical trial.
Major HIV-1 growth factors include an increased rise in prevalence of Human Immunodeficiency Virus 1 (HIV-1) which aids in stimulating the research and development of newer drugs to be profitable. The USFDA and EMA are supporting the HIV-1 therapeutics pipeline by encouraging the drug development process through different types of designations. Funding for the HIV response has increased significantly throughout the epidemic. Primarily, this growth has been driven by an increase in HIV awareness, increased spending on mandatory domestic care and treatment programs; as more people are living with Human Immunodeficiency Virus in the US, greater investments are needed to combat Human Immunodeficiency Virus in low and middle-income countries.
However, lack of resources associated with Human Immunodeficiency Virus treatment and diagnosis may at times occur as an obstruction in the Human Immunodeficiency Virus Market. Privacy and lack of anonymity, as well as social stigma revolving around the disease, are also a few of the prominent setbacks.
DelveInsight's, "Human Immunodeficiency Virus Type 1 (HIV-1) Infection – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline landscape covering the pipeline drug profiles, including clinical and non-clinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type and key companies involved like United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
DelveInsight's "Human Immunodeficiency Virus Type 1 (HIV-1) Infection - Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted Human Immunodeficiency Virus Type 1 (HIV-1) Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight's "Multiple Organ Dysfunction Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report proffers thorough details into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Dart Neuroscience, Corcept Therapeutics, Cerecin, and various others.
DelveInsight's 'Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030' report provide deep insights into the Narcolepsy market, epidemiology, pipeline therapies, and key companies including Cephalon Inc., Jazz Pharmaceuticals, and several others.
DelveInsight's, "Human Papillomavirus 16-positive (HPV16+) Cancers - Pipeline Insight, 2021," report provides comprehensive insights about 10+ pipeline drugs in Human Papillomavirus Vaccibody and 10+ key companies such as Genexine, Transgene, Inovio Pharmaceuticals, and others.
DelveInsight's "Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Autoimmune Hepatitis, historical and forecasted epidemiology as well as current treatment practices, emerging drugs, and unmet medical needs.
"Human Papillomavirus (HPV) Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Human Papillomavirus (HPV) market. A detailed picture of the Human Papillomavirus (HPV) pipeline landscape is provided, which includes the disease overview and Human Papillomavirus (HPV) treatment guidelines.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.